Shares of OvaScience Inc. (NASDAQ:OVAS) saw unusually-high trading volume on Monday . Approximately 357,221 shares traded hands during mid-day trading, an increase of 1% from the previous session’s volume of 352,706 shares.The stock last traded at $6.52 and had previously closed at $6.34.

OVAS has been the topic of a number of analyst reports. Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a research report on Tuesday, July 12th. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of OvaScience in a research note on Monday, April 25th. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Wednesday, August 10th. JMP Securities reissued a “neutral” rating on shares of OvaScience in a research note on Wednesday, August 10th. Finally, JPMorgan Chase & Co. reduced their price objective on OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. OvaScience presently has an average rating of “Hold” and a consensus price target of $10.98.

The stock’s market cap is $229.01 million. The stock’s 50-day moving average is $5.48 and its 200 day moving average is $7.07.

OvaScience (NASDAQ:OVAS) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. During the same period in the previous year, the business posted ($0.64) earnings per share. The business’s revenue for the quarter was up 530.0% on a year-over-year basis. On average, equities research analysts forecast that OvaScience Inc. will post ($2.75) EPS for the current fiscal year.

In other news, CEO Michelle Dipp purchased 425,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 1st. The stock was acquired at an average cost of $7.00 per share, with a total value of $2,975,000.00. Following the acquisition, the chief executive officer now owns 971,921 shares in the company, valued at approximately $6,803,447. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.